

# THE 7<sup>th</sup> ICOH INTERNATIONAL CONFERENCE ON WORK ENVIRONMENT AND CARDIOVASCULAR DISEASES

Bridging the gap between knowledge and preventive interventions  
at the workplace to reduce cardiovascular diseases.

MAY 3-5, 2017 - Varese, Italy

## **Neuromediated syncope and high risk activities**

**Monica Solbiati**


*Department of Internal Medicine, Fondazione IRCCS Ca' Granda, Ospedale  
Maggiore Policlinico, and Department of Clinical Sciences and Community  
Health, Università degli Studi di Milano - Milan, Italy*

May 3<sup>rd</sup> 2017

# Two twin brothers are brought to the ED after T-LoC

SAD

HAPPY





I work as a  
lawyer



- 55 years old;
- Lateral myocardial infarction 3 years ago;
- Current therapy: Aspirin 100 mg, Metoprolol 50 mg bid, Ramipril 5 mg, Simvastatin 40 mg;
- Syncope with no prodrome while going from the bed to the bathroom during the flu;
- ECG: sinus bradycardia 56 bpm, PR 240 msec, RBBB and left posterior fascicular block (previously unknown);
- No previous syncopal episodes;
- During ED ECG monitoring prolonged asystolic pause due to sudden-onset paroxysmal AV block.





I work as a  
high-rise  
window  
cleaner



- 55 years old;
- Unremarkable past medical history;
- Not under any medication;
- Faints while standing during a concert;
- He reports multiple previous episodes with or without prodromes in the past years;
- ED physical examination, vital signs and ECG are normal.

Admitted for  
permanent  
PM implant

Discharged  
home with a  
diagnosis of  
neuromediated  
syncope



# Happy



# ending?

No more episodes at the 3-month follow-up.

2 months later syncope at work with fall and severe injury.

**Clinical risk**

**Occupational risk**



# Does syncope affect workers' prognosis?



# Does syncope affect workers' prognosis?

JACC: CLINICAL ELECTROPHYSIOLOGY

© 2016 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION

PUBLISHED BY ELSEVIER

VOL. 2, NO. 2, 2016

ISSN 2405-500X/\$36.00

<http://dx.doi.org/10.1016/j.jacep.2015.10.006>

## Prospective Assessment of the Risk of Vasovagal Syncope During Driving



Vern Hsen Tan, MD, Debbie Ritchie, MN, Connor Maxey, BSc, Robert Sheldon, MD, PhD,  
on behalf of the POST Investigators



- To assess the likelihood of a motor vehicle accident causing serious risk or harm in patients with frequent vasovagal syncope (POST 1 and POST 2 patients), and compare this with international accident data;
- 418 patients (age  $38 \pm 17$  years) with a median of 10 lifetime faints and a median of 3 faints in the previous year;
- Total follow-up time was 323 years, or 0.77 years per person;
- A total of 174 subjects fainted, having a total of 615 faints;
- **Limitation: very selected population.**

**TABLE 2** Estimated Risk of Harm Caused by Syncope While Driving in the POST-1 and -2 Subjects

Item	Count or Frequency
Subjects fainted while driving, n	2
Subjects fainted while driving per year	2.59
Percent subjects fainted while driving	0.48%
Percent subjects fainted while driving per year	0.62%
Estimated risk of serious harm or death	0.0035%

The risk of harm according to the CCS Guidelines is (probability of fainting while driving per year)  $\times 0.02 \times 0.28$ .  
CCS = Canadian Cardiovascular Society; POST = Prevention of Syncope Trial.

**TABLE 4** Estimated Risk of Harm Caused by Syncope While Driving Compared With the Frequency of MVAs and Injuries in Alberta, Canada, the United Kingdom, and the United States

Location, Year (Ref. #)	MVAs, %	Injuries, %	Serious Injury, %	Death, %	Serious Injury and Death, %
Canada, 2012 (19,20)	0.56 (est)	0.51	0.044	0.009	0.053
United States, 2009 (21)	2.29	0.63	NR	0.013	>0.013
United Kingdom, 2013 (22,23)	0.49	0.52	0.078	0.0044	0.082
Country averages	$1.11 \pm 1.02$	$0.55 \pm 0.07$	0.061 (exc U.S.)	$0.009 \pm 0.004$	0.067 (exc U.S.)
CCS Guidelines (12)	<1	N/A	<0.005	<0.005	<0.005
Syncope	0.31	N/A	$\leq 0.0017$ (est)	$\leq 0.0017$ (est)	$\leq 0.0017$ (est)

The rates are expressed as likelihood of event per 100 driver-years, denoted as %.

est = estimated; exc = excluding; MVA = motor vehicle accident; NR = not reported; other abbreviation as in Table 2.

# Does syncope affect workers' prognosis?

Research

## Original Investigation

### Syncope and Motor Vehicle Crash Risk A Danish Nationwide Study

Anna-Karin Numé, MD; Gunnar Gislason, MD, PhD; Christine B. Christiansen, MD, PhD; Deewa Zahir, MB; Mark A. Hlatky, MD; Christian Torp-Pedersen, MD, DSc; Martin H. Ruwald, MD, PhD

*JAMA Intern Med.* 2016;176(4):503-510. doi:[10.1001/jamainternmed.2015.8606](https://doi.org/10.1001/jamainternmed.2015.8606)  
Published online February 29, 2016.

**Corresponding Author:** Anna-Karin Numé, MD, Department of Cardiology, Copenhagen University Gentofte Hospital, Kildegaardsvej 28, 8.3, Post 635, DK-2900 Hellerup, Denmark ([annakarin.nume@gmail.com](mailto:annakarin.nume@gmail.com)).

- All Danish residents between 2008 and 2012 who were at least 18 years old;
- 4265301 people, of whom 41039 had a first-time diagnosis of syncope from hospital or emergency department (sensitivity 63%, positive predictive value 95%);
- Median age of 66 (IQR 47-78) years; 51% women;
- During a median follow-up of 2.0 years, a total of 1791 patients with syncope (4.4%) experienced a motor vehicle crash that required medical evaluation in an emergency department or hospital; 0.3% of these crashes were fatal, and 78.1% resulted in crash-related injury;
- The crude incidence rates of motor vehicle crashes per 1000 person-years were higher among the syncope population (20.6; 95% CI, 19.7-21.6) compared with the general population (12.1; 95% CI, 12.0-12.1);
- Patients with syncope had a 2-fold higher RR of motor vehicle crashes compared with the general population (RR, 2.04; 95% CI, 1.95-2.14;  $P < .001$ );
- The average interval between syncope discharge and the occurrence of a crash was 315 (IQR 59-698) days.

# Does syncope affect workers' prognosis?

## Original Article

### **Syncope and Its Impact on Occupational Accidents and Employment**

#### **A Danish Nationwide Retrospective Cohort Study**

Anna-Karin Numé, MD; Kristian Kragholm, MD, PhD; Nicolas Carlson, MD;  
Søren L. Kristensen, MD, PhD; Henrik Bøggild, MD, PhD; Mark A. Hlatky, MD;  
Christian Torp-Pedersen, MD, DSc; Gunnar Gislason, MD, PhD; Martin H. Ruwald, MD, PhD

*(Circ Cardiovasc*

*Qual Outcomes.* 2017;10:e003202. DOI: 10.1161/CIRCOUTCOMES.116.003202.)



- All Danish residents between 2008 and 2012 who were 18 to 64 years;
- Among 3410148 eligible individuals, 21729 had a first-time diagnosis of syncope;
- Median age 48.4 years (IQR 33.0-59.5), and 10757 (49.5%) employed at time of the syncope event;
- Over a median follow-up of 3.2 years, 622 people with syncope had an occupational accident requiring hospitalization (2.1/100 person-years). In multiple Poisson regression analysis, the incidence rate ratio in the employed syncope population was higher than in the employed general population (1.44; 95% confidence interval [CI], 1.33–1.55) and more pronounced in people with recurrences (2.02; 95% CI, 1.47–2.78);
- The 2-year risk of termination of employment was 31.3% (95% CI, 30.4%–32.3%), which was twice the risk of the reference population (15.2%; 95% CI, 14.7%–15.7%).

## Prognosis Among Healthy Individuals Discharged With a Primary Diagnosis of Syncope

### Objectives

This study sought to examine the risk of major cardiac adverse events and death in a nationwide cohort of patients without previous comorbidity admitted for syncope.

### Background

Syncope is a common clinical event, but knowledge of prognosis is not fully elucidated in healthy individuals.

### Methods

Patients without previous comorbidity admitted for syncope in Denmark from 2001 to 2009 were identified in nationwide administrative registries and matched by sex and age with 5 control subjects from the Danish population. The risk of death or recurrent syncope, implantation of pacemaker or implantable cardioverter-defibrillator, and cardiovascular hospitalization were analyzed with multivariable Cox proportional hazard models.

### Results

We identified 37,017 patients with a first-time diagnosis of syncope and 185,085 control subjects; their median age was 47 years (interquartile range, 32 to 63 years) and 47% were male. A total of 3,023 (8.2%) and 14,251 (7.1%) deaths occurred in the syncope and the control population, respectively, yielding an event rate of 14.3 per 1,000 person-years (PY) in the syncope population. Multivariable Cox regression analysis demonstrated a significantly increased risk of all-cause mortality (hazard ratio [HR]: 1.06; 95% confidence interval [CI]: 1.02 to 1.10), cardiovascular hospitalization event rate of 26.5 per 1,000 PY (HR: 1.74; 95% CI: 1.68 to 1.80), recurrent syncope event rate of 45.1 per 1,000, stroke event rate of 6.8 per 1,000 PY (HR: 1.35; 95% CI: 1.27 to 1.44), and pacemaker or implantable cardioverter-defibrillator event rate of 4.2 per 1,000 PY (HR: 5.52; 95% CI: 4.67 to 5.73;  $p < 0.0001$ ).

### Conclusions

The first admission for syncope among healthy individuals significantly predicts the risk of all-cause mortality, stroke, cardiovascular hospitalization, device implantation, and recurrent syncope. (J Am Coll Cardiol 2013;61:325–32) © 2013 by the American College of Cardiology Foundation



# Assessing “low” risk patients in high risk settings

- Risk of recurrence;
- Risk of serious outcomes in case of recurrence;
- Syncope situation and precipitating factors.



# Risk of recurrence



Europace (2015) **17**, 300–308  
doi:10.1093/europace/euu327

**CLINICAL RESEARCH**  
*Syncope*

## Syncope recurrence and mortality: a systematic review

Table 2 Pooled incidence of mortality, syncope relapse, major events, and overall serious outcomes at different times								
Outcome	Time	Number of studies	Number of patients	Number of events	Pooled rate (%)	95% CI (%)	I <sup>2</sup> (%) <sup>b</sup>	Heterogeneity P-value <sup>c</sup>
Syncope recurrence	30 days	1 (S24)	380	1	0.3	0–1.8 <sup>a</sup>	0	–
	6 months	2 (S13; S20)	350	18	5.2	3.3–8.2	0	0.3915
	1 year	2 (S7; S22)	797	72	9.0	7.2–11.3	0	0.5987
	1.5 years	4 (S10; S16; S22; S24)	1254	202	16.1	14.2–18.3	0	0.9582
	2 years	2 (S21; S25)	164	36	22.0	16.3–29.1	0	0.4727

# Risk of recurrence

## Circulation

---

### ARTICLES


## Risk Factors for Syncope Recurrence After a Positive Tilt-Table↓ Test in Patients With Syncope

Robert Sheldon, Sarah Rose, Patricia Flanagan, Mary Lou Koshman, Shawn Killam

**DOI** <https://doi-org.pros.lib.unimi.it:2050/10.1161/01.CIR.93.5.973>

Circulation. 1996;93:973-981

- Multivariate proportional hazards analysis demonstrated that the most powerful predictor of a recurrence of syncope was the logarithm of the number of preceding syncopal spells ( $P < .001$ );
- The probability of a recurrence of syncope also varied with the logarithm of the frequency of preceding spells ( $P = .008$ );
- The median frequency of pretest spells was 0.3/month; after the tilt test, the median frequency dropped  $\approx 90\%$  to 0.03 per month.



# A quantitative model

Autonomic Neuroscience: Basic and Clinical 184 (2014) 46–52



Contents lists available at [ScienceDirect](#)

Autonomic Neuroscience: Basic and Clinical

journal homepage: [www.elsevier.com/locate/autneu](http://www.elsevier.com/locate/autneu)



## Driving and Working with Syncope



Franca Barbic <sup>a,\*</sup>, Giovanni Casazza <sup>b</sup>, Antonio Roberto Zamunér <sup>a,c</sup>, Giorgio Costantino <sup>d</sup>, Mauro Orlandi <sup>a</sup>,  
Franca Dipaola <sup>a</sup>, Chiara Capitanio <sup>a</sup>, Sara Achenza <sup>a</sup>, Robert Sheldon <sup>e</sup>, Raffaello Furlan <sup>a</sup>

<sup>a</sup> Internal Medicine, BIOMETRA Department, Humanitas Clinical and Research Center, Rozzano (MI), University of Milan, Italy

<sup>b</sup> Department of Biomedical and Clinical Sciences “L. Sacco”, University of Milan, Italy

<sup>c</sup> Department of Physical Therapy, Federal University of Sao Carlos, Brazil

<sup>d</sup> Division of Medicine and Pathophysiology, Department of Biomedical and Clinical Sciences “L. Sacco”, University of Milan, Italy

<sup>e</sup> Department of Cardiac Sciences, University of Calgary, Canada



- The *syncope recurrence risk* assessed 6 months after the event, in a working population ( $RR$ ). This risk is accounted for by individual factors such as syncope etiology, number of syncope spells before the reference event, patient's age, gender and comorbidities.
- The actual *job task duration* ( $T$ ).  $T$  furnishes the duration, i.e. the magnitude, of the “exposure” to a specific risk associated to the corresponding job task.
- The presence of *features facilitating* ( $FF$ ) a *syncope relapse* characterizing a specific job task. Based on the literature and on occupational medicine expert opinions we have identified 5 facilitating features ([Table 3](#)).
- The *estimated expected harm* ( $EH$ ) for the worker and/or for bystanders and others, likely to be produced by the worker's loss of consciousness, during the job task considered.

$$RI_i = FF_i \times EH_i$$

$$RI_W = RR_w \times (T_1 RI_1 + T_2 RI_2 + \dots + T_k RI_k)$$

# Future perspectives...

- Workers and physicians education (think and report);
- Prospective ad hoc studies;
- Management guidelines.

